B of A Securities Upgrades Axsome Therapeutics to Buy, Raises Price Target to $106
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has upgraded Axsome Therapeutics (NASDAQ:AXSM) from Neutral to Buy and raised the price target from $95 to $106.
August 06, 2024 | 10:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has upgraded Axsome Therapeutics from Neutral to Buy and increased the price target from $95 to $106, indicating a positive outlook for the stock.
The upgrade from Neutral to Buy and the increased price target suggest that B of A Securities sees strong potential in Axsome Therapeutics' future performance. This is likely to attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100